BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23040257)

  • 1. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder.
    Sadeghi S; Garcia JA
    Semin Oncol; 2012 Oct; 39(5):608-14. PubMed ID: 23040257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urothelial cancers: using biology to improve outcomes.
    Pezaro C; Liew MS; Davis ID
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted agents in second-line bladder cancer therapy.
    Gerullis H; Otto T; Ecke TH
    Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic chemotherapy for urothelial transitional cell carcinoma: an overview of toxicity.
    Moulder SL; Roth BJ
    Semin Urol Oncol; 2001 Aug; 19(3):194-201. PubMed ID: 11561987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder cancer: translating molecular genetic insights into clinical practice.
    Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
    Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in advanced urothelial carcinoma.
    Verdoorn BP; Kessler ER; Flaig TW
    Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic chemotherapy for urothelial cancer.
    Sonpavde G; Hutson TE; Berry WR
    Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
    Aparicio AM; Elkhouiery AB; Quinn DI
    Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
    Pollera CF; Nelli F
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of bladder cancer trials in the European Organization for Research and Treatment.
    de Wit R;
    Cancer; 2003 Apr; 97(8 Suppl):2120-6. PubMed ID: 12673705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic chemotherapy for advanced bladder cancer: update and controversies.
    Garcia JA; Dreicer R
    J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on chemotherapy for advanced bladder cancer.
    Rosenberg JE; Carroll PR; Small EJ
    J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
    Vaughn DJ
    Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy for superficial bladder cancer.
    Baselli EC; Greenberg RE
    Oncology (Williston Park); 2001 Jan; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Rosenberg JE
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1729-36. PubMed ID: 18062747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of chemotherapy for urothelial tract tumors.
    Sternberg CN; Scher HI
    Oncology (Williston Park); 1987 Jul; 1(5):41-50, 60. PubMed ID: 3079483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.